Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib + doxorubicin + dexamethasone in transplant-eligible relapsed multiple myeloma
ISRCTN81151751Phase 2Terminated
- Sponsor
- University of Leeds
- Start
- Apr 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 2, open-label trial of carfilzomib, doxorubicin and dexamethasone in multiple myeloma (MM) (3 arms), sponsored by University of Leeds. Primary endpoints: Dose-limiting toxicities and Partial response rate after four cycles. Started Apr 2011; status: terminated.
02
Drugs
carfilzomibdoxorubicindexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ISRCTN81151751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN81151751.